Novartis v. HEC Pharm: Supreme Court Petition Denied in MS Drug Patent Dispute
Novartis AG sought Supreme Court review of a patent dispute with HEC Pharm over US9187405B2, a patent covering S1P receptor modulators used to treat relapsing-remitting multiple sclerosis. The petition was denied in just 89 days, leaving the lower court's decision intact and the patent's enforceability status unchanged at the Supreme Court level.
Supreme Court declines to review Novartis MS drug patent dispute
Novartis AG filed a petition for certiorari at the U.S. Supreme Court on January 18, 2023, seeking review of a lower court decision in an infringement action concerning US9187405B2. The patent covers S1P receptor modulators indicated for relapsing-remitting multiple sclerosis — a commercially significant therapeutic category. The defendants, HEC Pharm Co., Ltd. and HEC Pharm USA, Inc., opposed the petition. Morrison & Foerster LLP represented Novartis, with Deanne Elizabeth Maynard as lead counsel; Stris & Maher LLP represented HEC Pharm, with Peter K. Stris as lead counsel.
The recorded basis of termination is 'Petition Dismissed'; the docket order states the petition was 'DENIED'. The Supreme Court's denial of certiorari means it declined to hear the case on its merits, leaving the lower court ruling undisturbed. No written opinion explaining the denial is disclosed in the available record, which is consistent with standard Supreme Court practice when certiorari is denied.
The petition was resolved in 89 days — a short window consistent with the Court's standard certiorari review cycle rather than any expedited procedure. The specific legal questions Novartis raised, and the grounds on which the Court declined review, are not detailed in the available public record. What remains clear is that HEC Pharm's position before the lower court stands, and Novartis has exhausted its appellate options at the Supreme Court level for this docket.
See Complete Case & Patent Analysis →Filing to Petition Dismissed in 89 days
89 days from petition to denial — an unusually swift resolution at the Supreme Court level
US9187405B2 — S1P receptor modulators for relapsing-remitting MS
Any company developing, manufacturing, or commercialising S1P receptor modulators for MS indications in the United States should treat US9187405B2 as a priority FTO target. The Supreme Court's denial of certiorari means the lower court's ruling on this patent is now final for this dispute, but the patent itself — and any related family members — may still pose risk to third parties not party to this litigation. Generic manufacturers, biosimilar developers, and innovators working on next-generation MS compounds are all potentially in scope.
Official order — verbatim text
The docket records the petition as 'DENIED', with the recorded basis of termination noted as 'Petition Dismissed'. A Supreme Court certiorari denial carries no precedential value and does not constitute a ruling on the merits of the underlying patent dispute; it reflects only that fewer than four Justices voted to grant review. The lower court's judgment on US9187405B2 therefore remains operative, and the specific reasoning of that lower court — not the Supreme Court's silence — is the legally significant record for both parties and third-party competitors.
Petition denied: what the Supreme Court's refusal means for both parties
What a denied certiorari petition means in practice
When the Supreme Court denies a petition for certiorari, it declines to review the lower court's decision. This is not a ruling on the merits — the Court does not endorse or reject the lower court's reasoning. However, the practical effect is that the lower court's judgment stands and becomes the operative resolution of the dispute. No further appeal within the U.S. federal court system is available to Novartis on this docket.
No merits adjudicationNovartis loses its last federal appellate avenue
The denial of certiorari means Novartis cannot obtain Supreme Court reversal of the lower court's ruling on US9187405B2. Whatever finding the lower court made regarding the S1P receptor modulator patent — whether on validity, infringement, or another ground — now stands as the final federal judicial determination on this dispute. Novartis's enforcement position against HEC Pharm through this litigation pathway is exhausted.
Lower decision standsHEC Pharm retains the benefit of the lower court ruling
HEC Pharm Co., Ltd. and HEC Pharm USA, Inc. successfully opposed the petition. With certiorari denied, the lower court outcome in their favour — the specific nature of which is not detailed in the available public record — is now final. This removes the overhang of Supreme Court review and provides HEC Pharm with greater certainty regarding its position in the relapsing-remitting MS drug market covered by the disputed patent.
Petition opposition succeededMS drug patent landscape: enforceability question now settled federally
The Supreme Court's refusal to intervene closes the federal judicial chapter on this particular challenge to US9187405B2. For other manufacturers operating in the S1P receptor modulator space — a class that includes treatments for relapsing-remitting MS — the lower court's ruling on this patent is now the controlling precedent for this dispute. Companies monitoring freedom-to-operate in this therapeutic category should review the lower court record directly.
Enforceability question resolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Swiss multinational pharmaceutical company — holder of US9187405B2Search in Eureka ↗ |
| Defendant | HEC Pharm Co., Ltd. | Company | HEC Pharm Co., Ltd. and HEC Pharm USA, Inc. — generic pharmaceutical manufacturersSearch in Eureka ↗ |
| Co-Defendant | HEC Pharm USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Deanne Elizabeth Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster, LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Peter K. Stris | Attorney | Counsel for HEC Pharm Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Stris & Maher LLP | Law Firm | Representing HEC Pharm Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
R&D signals in the S1P receptor modulator patent space
Forward-looking patent and innovation intelligence derived from the Novartis v. HEC Pharm dispute — relevant to MS drug developers and competitors in the S1P modulator space.
Novartis's S1P modulator filing activity beyond US9187405B2
Novartis's willingness to pursue this dispute to the Supreme Court suggests strong portfolio conviction in the S1P receptor modulator space. Mapping the continuation, divisional, and foreign counterpart filings around US9187405B2 may reveal additional claim coverage — including method-of-treatment, formulation, and dosing claims — that competitors and generic entrants have not yet assessed.
Continuation family riskFiling trends in S1P receptor modulator therapeutics for MS
The S1P receptor modulator class — which includes approved MS therapies — has attracted sustained patent filing activity from multiple innovators. Tracking global filing trends in this space can identify where new claim territories are emerging, which jurisdictions are most actively contested, and where white space exists for next-generation compound development.
MS drug IP landscapeHEC Pharm's patent position in the US generic MS drug market
HEC Pharm's successful opposition to Novartis's Supreme Court petition signals growing generic pharmaceutical IP sophistication in the MS space. Assessing HEC Pharm's own US patent filings and ANDA history provides insight into how established generic players are building defensive or offensive IP positions around S1P modulator compounds.
Generic entrant IP strategyAdjacent R&D opportunities near S1P receptor modulator claims
The claim boundaries established by US9187405B2 and the lower court's ruling may define white space for novel S1P modulator structures, alternative receptor subtypes (S1P2–S1P5), or differentiated delivery mechanisms. Teams exploring next-generation MS immunomodulators should map unoccupied claim territory relative to Novartis's published family.
White space in MS immunomodulationSimilar S1P modulator and MS drug patent disputes at federal level
Explore related pharmaceutical patent infringement cases involving S1P receptor modulators and MS therapeutics litigated in U.S. federal courts, including Supreme Court petitions.
What this case signals for the MS drug patent IP landscape
A denied Supreme Court petition in a pharmaceutical infringement action carries real commercial weight for every competitor in the S1P receptor modulator space.
Certiorari denial closes Novartis's federal litigation path on this patent
Patent holders facing an adverse lower court ruling who fail to secure Supreme Court review have exhausted U.S. federal appellate options. For competitors in the relapsing-remitting MS drug market, this signals reduced litigation risk from this specific docket — though other enforcement mechanisms and separate proceedings remain possible.
S1P receptor modulator patents remain commercially critical to monitor
US9187405B2 covers a therapeutically significant product class. The closure of this Supreme Court petition does not resolve the broader patent landscape for S1P modulators. Companies developing or commercialising treatments in this space should conduct updated freedom-to-operate analysis against the full Novartis portfolio in this domain.
Novartis v HEC — key questions answered
The U.S. Supreme Court denied Novartis's petition for certiorari in Case No. 22-671. The recorded basis of termination is 'Petition Dismissed'. The petition was filed on January 18, 2023 and denied on April 17, 2023 — a period of 89 days. No merits opinion was issued; the lower court's ruling on US9187405B2 was left undisturbed.
The patent at issue is US9187405B2, filed under application number US14/257342. It covers S1P receptor modulators for the treatment of relapsing-remitting multiple sclerosis. The underlying action was characterised as an infringement action, consistent with ANDA-related patent litigation common in the branded pharmaceutical sector.
No. A denial of certiorari is not a ruling on the merits. The Supreme Court's denial means fewer than four Justices voted to grant review; it does not signal agreement or disagreement with the lower court's reasoning. The lower court's judgment on US9187405B2 stands as the operative resolution, but the Supreme Court has not endorsed that reasoning.
For generic and biosimilar manufacturers in the S1P receptor modulator space, the denial closes Novartis's federal appellate avenue on this specific docket. However, Novartis's broader patent portfolio in the MS space may include additional patents with independent claim coverage. Companies should conduct updated FTO analysis against the full Novartis S1P modulator family before entering the market.
Novartis AG was represented by Morrison & Foerster LLP, with Deanne Elizabeth Maynard as lead counsel. HEC Pharm Co., Ltd. and HEC Pharm USA, Inc. were represented by Stris & Maher LLP, with Peter K. Stris as lead counsel.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.